Phase I trial of PCNU

L. A. Kalman; R. J. Gralla; E. S. Casper; M. G. Kris; C. Gordon; T. M. Woodcock

Phase I trial of PCNU

L. A. Kalman, R. J. Gralla, E. S. Casper, M. G. Kris, C. Gordon, T. M. Woodcock

Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m² in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m². Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m² iv for each 5-day course (20-25 mg/m²/day) is recommended for phase II studies.

Original language	English (US)
Pages (from-to)	1027-1029
Number of pages	3
Journal	Cancer Treatment Reports
Volume	67
Issue number	11
State	Published - Dec 1 1983

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{27ff6b566e734207847860f08a63070a,

title = "Phase I trial of PCNU",

abstract = "In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.",

author = "Kalman, {L. A.} and Gralla, {R. J.} and Casper, {E. S.} and Kris, {M. G.} and C. Gordon and Woodcock, {T. M.}",

year = "1983",

month = dec,

day = "1",

language = "English (US)",

volume = "67",

pages = "1027--1029",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Phase I trial of PCNU

AU - Kalman, L. A.

AU - Gralla, R. J.

AU - Casper, E. S.

AU - Kris, M. G.

AU - Gordon, C.

AU - Woodcock, T. M.

PY - 1983/12/1

Y1 - 1983/12/1

N2 - In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.

AB - In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.

UR - http://www.scopus.com/inward/record.url?scp=0021041079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021041079&partnerID=8YFLogxK

M3 - Article

C2 - 6315229

AN - SCOPUS:0021041079

SN - 0027-8874

VL - 67

SP - 1027

EP - 1029

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 11

ER -

Phase I trial of PCNU

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this